Skip to main content

Table 1 Independent prognostic biomarkers in resected colorectal liver metastases

From: Immunohistochemical investigation of prognostic biomarkers in resected colorectal liver metastases: a systematic review and meta-analysis

Biomarker References Year N Hazard ratio (95% CI) Detection ratea p-value
Self-sufficiency in growth signals
 Ki-67 Ivanecz et al. [64] 2014 98 0.82 (0.68–0.98) 27/98 (28%) 0.038
 EGFR Goos et al. [120] 2014 323 1.54 (1.07–2.22)c 121/323 (37%) 0.02
 RKIP Kim et al. [77] 2012 68 0.19 (0.09–0.45)c 22/68 (32%) 0.014
Insensitivity to anti-growth signals
 p53 Nitti et al. [59] 1998 69 2.53 (1.84–3.22) 44/69 (64%) 0.008
Evading programmed cell death
 TRX-1 Noike et al. [142] 2008 84 0.41 (0.24–0.71) 37/84 (44%) 0.002
 FAS/CD95 Onodera et al. [191] 2005 85 3.254 (1.00–10.49) 30/85 (35%) 0.048
Limitless replicative potential
 hTERT Dômont et al. [40] 2005 201 2.03 (1.46–2.82) 86/201 (43%) < 0.001
Sustained angiogenesis
 CD34 Miyagawa et al. [131] 2002 71 2.46 (1.13–5.37) 38/71 (54%) 0.023
  Nanashima et al. [132] 2009 139 2.71 (1.15–6.42) 69/139 (50%) 0.023
 PTGS2/COX-2 Goos et al. [120] 2014 351 1.59 (1.14–2.26)c 85/351 (24%) 0.01
 VEGFA Goos et al. [198] 2016 335 1.50 (1.066–2.111)c 101/335 (30%) 0.02
Activating invasion and metastasis
 TSP-1 Sutton et al. [159] 2005 182 1.82 (1.00–3.10) 45/182 (25%) 0.01
  Teraoku et al. [160] 2016 94 0.38 (0.12–0.99)c 35/94 (63%) < 0.05
 CAV-1 Neofytou et al. [156] 2017 108 0.40 (0.21–0.78)c 61/108 (56%) 0.007
 KISS1 Zhu et al. [172] 2015 55 0.20 (0.05–0.91) 19/55 (35%) 0.037
 FRZB Shen et al. [21] 2015 136 2.552 (1.86–3.64) 89/136 (65%) < 0.001
Deregulated metabolism
 Glucose transporter 1 (GLUT1/SLC2A1) Goos et al. [198] 2016 350 0.65 (0.51–0.863)c 179/350 (51%) < 0.01
Immune evasion/suppression
 MHChiCD3hi Turcotte et al. [213] 2014 154 0.36 (0.20–0.67) 31/154 (20%) 0.001
 CD3+CD8 Wang et al. [212] 2018 249 0.69 (0.59–0.80) 90/249 (36%) < 0.001
 CD45RO Brunner et al. [211] 2014 201b 0.46 (0.28–0.73)c 155/201 (77%) 0.001
   2014 201b 0.25 (0.10–0.64)c 155/201 (77%) 0.004
 plgR Liu et al. [179] 2014 136 2.673 (1.87–3.76) 86/136 (63%) < 0.001
 CD83 Miyagawa et al. [210] 2004 70 0.42 (0.23–0.76)c 44/70 (63%) 0.004
 Tryptase Suzuki et al. [209] 2015 135 17.3 (4.80–62) 73/135 (54%) < 0.01
 CD68 Miyagawa et al. [131] 2002 71 2.127 (1.01–4.50) 36/71 (51%) 0.049
Genome instability
 Aurora kinase A Goos et al. [109] 2013 343 1.66 (1.08–2.54)c 115/243 (34%) 0.02
Other markers
 CD133 Yamamoto et al. [91] 2014 103 0.320 (0.13–0.81) 46/103 (45%) 0.016
 APOBEC3G Lan et al. [185] 2014 136 2.582 (1.83–3.63) 91/136 (67%) < 0.001
 CDX2 Shigematsu et al. [217] 2018 396 0.415 (0.26–0.66) 360/396 (91%) < 0.001
  1. aPercentage of samples higher than cutoff
  2. bPatient cohort divided into separate analysis
  3. cInverted HR